Piramal Pharma Ltd

NSE: PPLPHARMA · BSE: 543635 · Pharmaceuticals & Biotechnology · 32 announcements

Share price: ₹202.67
Market cap: ₹26,982 Cr
Revenue (annual): ₹8,869 Cr
Net profit (annual): ₹-325.9 Cr
P/E (TTM): -86.0×Sector 47.4×
Promoter holding: 34.80%-0.06% QoQ
FII holding: 12.51%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

13 Apr 2026 10:20 IST BSE

Piramal Pharma Regulatory Approval

Piramal Pharma Limited successfully closed its US FDA inspection at its Lexington, USA manufacturing facility. The US FDA issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification. This marks the formal and successful conclusion of the inspection initiated in December 2025.

Read the filing ↗

6 Apr 2026 18:25 IST BSE

Other Announcement

Piramal Pharma Other Announcement

Piramal Pharma Ltd received an improved ESG rating of '64' from NSE Sustainability for FY 2024-25, up from the previous score of 61. The voluntary rating reflects the company's progress in sustainability and responsible operations based on public disclosures.

Read the filing ↗